GENOSYL® Delivery System

The First & Only Tankless Inhaled Nitric Oxide Delivery System.

Learn More

Please fill out the following form to learn more about the GENOSYL® Delivery System:

More about Inhaled Nitric Oxide

Nitric oxide

A compound of one atom of nitrogen and one atom of oxygen—is a critically important molecule involved in many physiological and disease processes. This “startlingly simple” compound was dubbed Molecule of the Year in 1992 as it “unites neuroscience, physiology, and immunology, and revises scientists’ understanding of how cells communicate and defend themselves.”

Inhaled Nitric Oxide

Inhaled Nitric Oxide as a therapeutic agent is ideally suited to its purpose—to effect dilation of pulmonary vessels, thereby lowering pulmonary artery pressures. Importantly, delivered to the lung, and with a very short half-life of a few seconds in the blood, the effect of inhaled nitric oxide is selective for the pulmonary vasculature, rather than systemic, as with other types of vasodilators.

GENOSYL® (nitric oxide)

GENOSYL® (nitric oxide) gas for inhalation, relaxes vascular smooth muscle cells, which leads to vasodilation of the pulmonary capillaries. GENOSYL appears to increase the partial pressure of arterial oxygen (PaO2) by dilating pulmonary vessels in better ventilated areas of the lung, redistributing pulmonary blood flow away from lung regions with low ventilation/perfusion (V/Q) ratios toward regions with normal ratios.

Indication & Safety Information

GENOSYL® is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.

  • GENOSYL is contraindicated in the treatment of neonates dependent on right-to-left shunting of blood.
  • Abrupt discontinuation of GENOSYL (nitric oxide) gas, for inhalation may lead to worsening oxygenation and increasing pulmonary artery pressure.
  • Methemoglobin, NO2 and PaO2 should be monitored during nitric oxide administration.
  • In patients with pre-existing left ventricular dysfunction, GENOSYL may increase pulmonary capillary wedge pressure leading to pulmonary edema. The most common adverse reaction is hypotension.
  • Nitric oxide donor compounds may have an additive effect with GENOSYL on the risk of developing methemoglobinemia.
  • Only validated ventilator systems or nasal cannulas should be used in conjunction with GENOSYL.
  • See package insert for additional Important Safety Information.